Past Forum: 2022 - World Medical Innovation Forum
WMIF Main Site

Past Forum: 2022

Boston

Summary

The eight annual World Medical Innovation Forum was back in person in Boston.

This year, we gathered to discuss the extraordinary opportunities in gene and cell therapy and the profound impact they will have on medicine. In more than thirty sessions over the course of three days, Mass General Brigham’s Harvard faculty, industry experts and leading investors and entrepreneurs explored the technologies and challenges of gene and cell therapy as we continue to bring life-changing breakthroughs to our patients and millions around the world.

The World Medical Innovation Forum was established to reaffirm the importance of collaborative innovation—academia, industry and government working together to create solutions for medicine’s great challenges. Our goal is to provide actionable insights for Forum participants. We are grateful to the nearly 200 senior executives, investors, Harvard clinicians and investigators who shared their perspectives as speakers.

Speakers

Laura Aguilar

Laura Aguilar, MD, PhD  

  • Co-Founder, Candel Therapeutics

Galit Alter, PhD  

  • Principal Investigator, Ragon Institute, MGH
  • Professor of Medicine, HMS
Irina Antonijevic

Irina Antonijevic, MD, PhD  

  • CMO and Head of R&D, Triplet Therapeutics, Inc.

Natalie Artzi, PhD  

  • Assistant Professor of Medicine, HMS
Christopher Baum

Christopher Baum, MD  

  • Chairman of the Board of Directors, Berlin Institute of Health at Charité (BIH)
James Beck

James Beck, PhD  

  • CSO, Parkinson’s Foundation
Fengfeng Bei

Fengfeng Bei, PhD  

  • Principal Investigator, Department of Neurosurgery, BWH
  • Assistant Professor of Neurosurgery, HMS
Paul Biddinger

Paul Biddinger, MD  

  • Chief Preparedness and Continuity Officer, Mass General Brigham
  • Associate Professor of Emergency Medicine, HMS
John Bishai

John Bishai, PhD  

  • Managing Director, Global Investment Banking, BofA Securities
Joseph Bonventre

Joseph Bonventre, MD, PhD  

  • Chief, Division of Renal Medicine, BWH
  • Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS

Albert Bourla, PhD  

  • CEO, Pfizer Inc.
Sarah Boyce

Sarah Boyce  

  • President & CEO, Avidity Biosciences, Inc.
Robert Bradway

Robert Bradway  

  • CEO, Amgen
Helen Branswell

Helen Branswell  

  • Senior Writer, STAT

David Brown, MD  

  • President, Massachusetts General Hospital
  • Executive Vice President, Mass General Brigham
Lynn Bry

Lynn Bry, MD, PhD  

  • Director, Massachusetts Host-Microbiome Center, BWH
  • Associate Professor of Pathology, HMS
Jim Burns

Jim Burns, PhD  

  • CEO, Locanabio
Greg Butz

Greg Butz  

  • Managing Director, Head of Life Sciences Investment Banking, BofA Securities
Pablo Cagnoni

Pablo Cagnoni, MD  

  • CEO, Rubius Therapeutics
Robert Califf

Robert Califf, MD  

  • Commissioner of Food and Drugs, US Food and Drug Administration

Bob Carter, MD, PhD  

  • Chairman, Department of Neurosurgery, MGH
  • William and Elizabeth Sweet Professor of Neurosurgery, HMS
Marc Casper

Marc Casper  

  • CEO, ThermoFisher
Miceal Chamberlain

Miceal Chamberlain  

  • President of Massachusetts, Northeast Region Executive, Bank of America
Anil Chandraker

Anil Chandraker, MD  

  • Medical Director of Kidney and Pancreas Transplantation, BWH
  • Associate Professor of Medicine, HMS
Zheng-yi Chen

Zheng-Yi Chen, DPhil  

  • Associate Scientist, Eaton-Peabody Laboratories, Mass Eye and Ear
  • Associate Professor of Otolaryngology Head and Neck Surgery, HMS

Nino Chiocca, MD, PhD  

  • Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH
  • Harvey W. Cushing Professor of Neurosurgery, HMS
Choi-Fong Cho

Choi-Fong Cho, PhD  

  • Assistant Professor of Neurosurgery, BWH, HMS
Shelley Chu

Shelley Chu, MD, PhD  

  • Partner, Lightspeed

Chris Coburn  

  • Chief Innovation Officer, Mass General Brigham
Monica Coenraads

Monica Coenraads  

  • CEO, Rett Syndrome Research Trust
Bertha Coombs

Bertha Coombs  

  • Reporter, CNBC
David Corey

David Corey, PhD  

  • Bertarelli Professor of Translational Medical Science, Neurobiology, HMS
Susan Cotman

Susan Cotman, PhD  

  • Assistant in Neuroscience, Center for Genomic Medicine, MGH
  • Assistant Professor of Neurology, HMS
Christina Coughlin

Christina Coughlin, MD, PhD  

  • CEO, CytoImmune

Merit Cudkowicz, MD  

  • Chair, Dept of Neurology, MGH
  • Julieanne Dorn Professor of Neurology, HMS
Derik De Bruin

Derik de Bruin, PhD  

  • Managing Director, Global Research, BofA Securities
Albert Edge

Albert Edge, PhD  

  • Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear

Florian Eichler, MD  

  • Director, Center for Rare Neurological Diseases, MGH
  • Associate Professor of Neurology, HMS
Seth Ettenberg

Seth Ettenberg, PhD  

  • President & CEO, BlueRock Therapeutics
Rick Fair

Rick Fair  

  • President & CEO, Bellicum
Anne Finucane

Anne Finucane  

  • Chairman of the Board, Bank of America Europe
John Fish

John Fish  

  • Chairman & CEO, Suffolk
  • Chair, Brigham and Women’s Hospital

Meredith Fisher, PhD  

  • Partner, Mass General Brigham Ventures
Alexandria Forbes

Alexandria Forbes, PhD  

  • President & CEO, MeiraGTx

Jean-François Formela, MD  

  • Partner, Atlas Venture
Christine Fox

Christine Fox  

  • President, Novartis Gene Therapies
Matthew Frigault

Matthew Frigault, MD  

  • Clinical Director, Cellular Immunotherapy Program, MGH
  • Assistant Professor of Medicine, HMS
Nick Galakatos

Nicholas Galakatos, PhD  

  • Global Head of Life Sciences, Blackstone
Annie Ganot

Annie Ganot  

  • VP, Head of Patient Advocacy, Solid Biosciences
Jason Gerberry

Jason Gerberry  

  • Managing Director, Global Research, BofA Securities
Michael Gilmore

Michael Gilmore, PhD  

  • Chief Scientific Officer, Mass Eye and Ear
  • Sir William Osler Professor of Ophthalmology, HMS

Allan Goldstein, MD  

  • Chief of Pediatric Surgery, MGH
  • Surgeon-in-Chief, MassGeneral for Children
  • Marshall K. Bartlett Professor of Surgery, HMS
Robert Green

Robert Green, MD  

  • Director, Genomes2People Research Program, BWH
  • Professor of Medicine, HMS
Yulia Grishchuk

Yulia Grishchuk, PhD  

  • Assistant Investigator, Center for Genomic Medicine, MGH
  • Assistant Professor of Neurology, HMS
Stephen Haggarty

Stephen Haggarty, PhD  

  • Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine, MGH
  • Associate Professor of Neurology, HMS

David Hallal  

  • Chairman & CEO, ElevateBio
Alexandria Hammond

Alexandria Hammond, PhD  

  • Associate, Global Research, BofA Securities

Erin Harris  

  • Chief Editor, Cell & Gene
Greg Harrison

Greg Harrison  

  • Vice President, Global Research, BofA Securities

Rachel Haurwitz, PhD  

  • President & CEO, Caribou Biosciences
Kristen Hege

Kristen Hege, MD  

  • Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb
Todd Herrington

Todd Herrington, MD, PhD  

  • Director, Deep Brain Stimulation Program, MGH
  • Assistant Professor of Neurology, HMS
Robert Higgins

Robert Higgins, MD, MSHA  

  • President, Brigham and Women’s Hospital
  • Executive Vice President, Mass General Brigham
Colin Hill

Colin Hill  

  • CEO, GNS Healthcare

Susan Hockfield, PhD  

  • President Emerita, MIT
Ole Isacson

Ole Isacson, MD, PhD  

  • Director, Neuroregeneration Research Institute, McLean
  • Professor of Neurology & Neuroscience, HMS
Max Jan

Max Jan, PhD  

  • Principal Investigator, Center for Cancer Research, MGH
  • Assistant Professor of Pathology, HMS

J. Keith Joung, MD, PhD  

  • Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH
  • Professor of Pathology, HMS
Carl June

Carl June, MD  

  • Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
Staci Kallish

Staci Kallish, DO  

  • President, Board of Directors, National Tay Sachs and Allied Diseases
  • Medical Geneticist, Associate Professor of Clinical Medicine, Penn Medicine
Rosana Kapeller

Rosana Kapeller, MD, PhD  

  • Co-Founder, President & CEO, ROME Therapeutics
Sekar Kathiresan

Sekar Kathiresan, MD  

  • CEO, Verve Therapeutics
Jason Kelly

Jason Kelly, PhD  

  • Co-Founder & CEO, Ginkgo Bioworks
Kwang-Soo Kim

Kwang-Soo Kim, PhD  

  • Director, Molecular Neurobiology Laboratory, McLean
  • Professor of Neuroscience and Psychiatry, HMS
Roger Kitterman

Roger Kitterman  

  • VP, Mass General Brigham Ventures
Anne Klibanski

Anne Klibanski, MD  

  • President & CEO, Mass General Brigham
  • Laurie Carrol Guthart Professor of Medicine, HMS
Stephen Knight

Stephen Knight, MD  

  • President & Managing Partner, F-Prime Capital
Adam Koppel, MD, PhD

Adam Koppel, MD, PhD  

  • Managing Director, Bain Capital Life Sciences

Jonathan Kraft  

  • President, The Kraft Group
  • Chairman of the Board of Trustees, MGH
Anna Krichevsky

Anna Krichevsky, PhD  

  • Associate Professor of Neurology, BWH, HMS
Daniel Krizek

Daniel Krizek  

  • Portfolio Manager, Citadel
Dan Kuritzkes

Daniel Kuritzkes, MD  

  • Chief, Division of Infectious Diseases, BWH
  • Harriet Ryan Albee Professor of Medicine, HMS
Jeannie Lee

Jeannie Lee, MD, PhD  

  • Molecular Biologist, MGH
  • Professor of Genetics, HMS

Nick Leschly  

  • CEO, 2seventy bio
Josh Mandel-Brehm

Josh Mandel-Brehm  

  • President & CEO, CAMP4 Therapeutics
Joel Marcus

Joel Marcus  

  • Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.

James Markmann, MD, PhD  

  • Chief, Division of Transplant Surgery, MGH
  • Claude E. Welch Professor of Surgery, HMS

Peter Marks, MD, PhD  

  • Director, Center for Biologics Evaluation and Research, FDA
Marcela Maus

Marcela Maus, MD, PhD  

  • Director, Cellular Immunotherapy Program, Cancer Center, MGH
  • Associate Professor, Medicine, HMS
Terry McGuire

Terry McGuire  

  • Founding Partner, Polaris Partners
Rachel McMinn

Rachel McMinn, PhD  

  • Founder & CEO, Neurogene
Geoff Meacham

Geoff Meacham  

  • Managing Director, Global Research, BofA Securities
Maria Millan

Maria Millan, MD  

  • President & CEO, California Institute for Regenerative Medicine
Marco Mineo

Marco Mineo, MD  

  • Instructor in Neurosurgery, BWH, HMS
Rick Modi

Rick Modi  

  • CEO, Affinia Therapeutics
Brian Moynihan

Brian Moynihan  

  • Chair & CEO, Bank of America
Shu Mukherjee

Sumit Mukherjee  

  • Managing Director & Head of Healthcare in Equity Capital Markets, BofA Securities
Richard Mulligan

Richard Mulligan, PhD  

  • Mallinckrodt Professor of Genetics, Emeritus, HMS
  • Executive Vice Chairman, Sana Biotechnology, Inc
Chris Murphy

Christopher Murphy  

  • Vice President Viral Vector Services, Thermo Fisher
Luigi Naldini

Luigi Naldini, MD, PhD  

  • Director, San Raffaele Telethon Institute for Gene Therapy

Amir Nashat, PhD  

  • Managing Partner, Polaris Ventures
Sarah Nikiforow

Sarah Nikiforow, MD, PhD  

  • Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI
  • Assistant Professor, HMS
Rebecca Oberman

Rebecca Oberman, PhD  

  • Executive Director, Mucolipidosis Type IV (ML4) Foundation
Michael Paglia

Michael Paglia  

  • COO, ElevateBio BaseCamp, ElevateBio
Spyros Papapetropoulos

Spyros Papapetropoulos, MD, PhD  

  • CMO, Vigil Neuroscience

Pierpaolo Peruzzi, MD, PhD  

  • Neurosurgeon and Principal Investigator, BWH
  • Assistant Professor of Neurosurgery, HMS
Andy Plump

Andrew Plump, MD, PhD  

  • President, R&D, Takeda
Mark Poznansky

Mark Poznansky, MD, PhD  

  • Director, Vaccine and Immunotherapy Center, MGH
  • Professor of Medicine, HMS
Francisco Quintana

Francisco Quintana, PhD  

  • Professor, Neurology, Ann Romney Center for Neurologic Diseases, BWH
  • Kuchroo Weiner Distinguished Professor of Neuroimmunology, BWH
Harith Rajagopalan

Harith Rajagopalan, MD, PhD  

  • CEO & Co-Founder, Fractyl Health
Vijaya Ramesh

Vijaya Ramesh, PhD  

  • Co-Director of Neuroscience, Associate Geneticist in Neurology, MGH
  • Professor of Neurology, HMS
Richard Ransohoff

Richard Ransohoff, MD  

  • CMO, Abata Therapeutics
  • Venture Partner, Third Rock Ventures
Arati Rao

Arati Rao, MD  

  • Senior Vice President, Clinical Development, PACT Pharma
Kendra Rose

Kendra Rose, PhD  

  • VP, Head of New Platforms, Ophthalmology and Hemophilia, Bayer
John Rossi

John Rossi  

  • VP Head of Translational Medicine, Syncopation Life Sciences
Issi Rozen

Issi Rozen  

  • Venture Partner, GV
Michael Ryskin

Michael Ryskin  

  • Director, Global Research, BofA Securities

Bastiano Sanna, PhD  

  • EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals

Vicki Sato, PhD  

  • Chairman of the Board, Vir Biotechnology
  • Chairman, Denali Therapeutics

David Scadden, MD  

  • Director, Center for Regenerative Medicine, MGH
  • Gerald and Darlene Jordan Professor of Medicine, HMS

Jeffrey Schweitzer, MD, PhD  

  • Neurosurgeon, MGH
  • Assistant Professor of Neurosurgery, HMS

Christine Seidman, MD  

  • Director, Cardiovascular Genetics Center, BWH
  • Smith Professor of Medicine & Genetics, HMS

Laura Sepp-Lorenzino, PhD  

  • Chief Scientific Officer, Executive Vice President, Intellia Therapeutics
Dhvanit Shah

Dhvanit Shah, PhD  

  • President & CEO, Garuda Therapeutics

Khalid Shah, PhD  

  • Vice Chairman of Research, Department of Neurosurgery, BWH
  • Professor, HMS
Phillip Sharp

Phillip Sharp, PhD  

  • Institute Professor and Professor of Biology, Koch Institute for Integrative Cancer Research at MIT
  • Co-Founder, Alnylam Pharmaceuticals, Inc.
Ned Sharpless

Norman Sharpless, MD  

  • Former Director, National Cancer Institute

Christi Shaw  

  • CEO, Kite, a Gilead Company
Adam Shaywitz

Adam Shaywitz, MD, PhD  

  • CMO, BridgeBio Gene Therapy

Angela Shen, MD  

  • Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
Erica Shenoy

Erica Shenoy, MD, PhD  

  • Associate Chief, Infection Control Unit, MGH
  • Associate Professor of Medicine, HMS
Singhvi Rahul

Rahul Singhvi, ScD  

  • CEO, National Resilience, Inc.
Dan Skovronsky

Daniel Skovronsky, MD, PhD  

  • Senior Vice President, Chief Scientific and Medical Officer, Eli Lilly and Company

Susan Slaugenhaupt, PhD  

  • Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr. Endowed Chair, Mass General Research Institute
  • Professor, Neurology, HMS

Scott Sperling  

  • Co-Chief Executive Officer, Thomas H. Lee Partners
  • Chairman of the Board of Directors, Mass General Brigham
Catherine Stehman-Breen

Catherine Stehman-Breen, MD  

  • CEO, Chroma Medicine
Beth Stevens

Beth Stevens, PhD  

  • HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children’s Hospital
  • Associate Professor of Neurology, HMS
Alec Stranahan

Alec Stranahan, PhD  

  • Vice President, Equity Research, BofA Securities
Bakhos Tannous

Bakhos Tannous, PhD  

  • Director, Experimental Therapeutics Unit, Director, Viral Vector Core, MGH
  • Professor of Neurology, HMS

Rudolph Tanzi, PhD  

  • Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH
  • Joseph P. and Rose F. Kennedy Professor of Neurology, HMS

Ravi Thadhani, MD  

  • Chief Academic Officer, Mass General Brigham
Luk Vandenberghe

Luk Vandenberghe, PhD  

  • Grousbeck Associate Professor in Gene Therapy, Mass General Brigham (on leave)
Demetrios Vavvas

Demetrios Vavvas, MD, PhD  

  • Associate Director of the Retina Service, Mass Eye and Ear
  • Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS

Rusty Williams, MD, PhD  

  • Chairman & CEO, Walking Fish Therapeutics
Janet Wu

Janet Wu  

  • Anchor/Reporter, Bloomberg
Michael Young

Michael Young, PhD  

  • Director, Minda de Gunzburg Center for Retinal Regeneration, Associate Scientist, Schepens Eye Research Institute, Mass Eye and Ear
  • Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute, HMS
Richard Young

Richard Young, PhD  

  • Professor, Whitehead Institute, MIT
Nerea Zabaleta

Nerea Zabaleta, PhD  

  • Principal Investigator, Grousbeck Gene Therapy Center, Mass Eye and Ear
  • Instructor in Ophthalmology, HMS

Jason Zemansky, PhD  

  • Vice President, Global Research, BofA Securities
Ran Zheng

Ran Zheng  

  • CEO, Landmark Bio

Panels

Monday, May 2, 2022

First Look: 8 rapid fire presentations on Mass General Brigham’s new GCT technologies

  • Moderator: Meredith Fisher, PhD, Partner, Mass General Brigham Ventures
  • Moderator: Roger Kitterman, VP, Mass General Brigham Ventures

Presenters:

  • Bakhos Tannous, PhD, Director, Experimental Therapeutics Unit, Director, Viral Vector Core, MGH; Professor of Neurology, HMS
  • Vijaya Ramesh, PhD, Co-Director of Neuroscience, Associate Geneticist in Neurology, MGH; Professor of Neurology, HMS
  • Anna Krichevsky, PhD, Associate Professor of Neurology, BWH, HMS
  • Nerea Zabaleta, PhD, Principal Investigator, Grousbeck Gene Therapy Center, Mass Eye and Ear; Instructor in Ophthalmology, HMS
  • Francisco Quintana, PhD, Professor, Neurology, Ann Romney Center for Neurologic Diseases, BWH; Kuchroo Weiner Distinguished Professor of Neuroimmunology, BWH
  • Stephen Haggarty, PhD, Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine, MGH; Associate Professor of Neurology, HMS
  • Michael Young, PhD, Director, Minda de Gunzburg Center for Retinal Regeneration, Associate Scientist, Schepens Eye Research Institute, Mass Eye and Ear; Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute, HMS
  • Max Jan, MD, PhD, Principal Investigator, Center for Cancer Research, MGH; Assistant Professor of Pathology, HMS

First Look: 8 rapid fire presentations on Mass General Brigham’s new GCT technologies

  • Moderator: Meredith Fisher, PhD, Partner, Mass General Brigham Ventures
  • Moderator: Roger Kitterman, VP, Mass General Brigham Ventures

Presenters:

  • Choi-Fong Cho, PhD, Assistant Professor of Neurosurgery, BWH, HMS
  • Yulia Grishchuk, PhD, Assistant Investigator, Center for Genomic Medicine, MGH; Assistant Professor of Neurology, HMS
  • Lynn Bry, MD, PhD, Director, Massachusetts Host-Microbiome Center, BWH; Associate Professor of Pathology, HMS
  • David Corey, PhD, Bertarelli Professor of Translational Medical Science, Neurobiology, HMS
  • Anil Chandraker, MD, Medical Director of Kidney and Pancreas Transplantation, BWH; Associate Professor of Medicine, HMS
  • Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS
  • Marco Mineo, PhD, Instructor in Neurosurgery, BWH, HMS
  • Susan Cotman, PhD, Assistant in Neuroscience, Center for Genomic Medicine, MGH; Assistant Professor of Neurology, HMS

THE DR. IS IN | Gene and Epigenetic Editing in the Development of Treatment for Deafness

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Albert Edge, PhD, Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear 

THE DR. IS IN | Single Gene Correction in the Brain: Delivering Where it Matters Most

  • Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
  • Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor of Neurology, HMS 

THE DR. IS IN | Repair, Replace, Regrow: The Advancement of Regenerative Medicine

  • Moderator: Jason Zemansky, PhD, Vice President, Global Research, BofA Securities
  • Joseph Bonventre, MD, PhD, Chief, Division of Renal Medicine, BWH; Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS
  • David Scadden, MD, Director, Center for Regenerative Medicine, MGH; Gerald and Darlene Jordan Professor of Medicine, HMS 

THE DR. IS IN | Smart Materials: Non-viral Vectors for Gene Therapy

  • Moderator: Alec Stranahan, PhD, Vice President, Equity Research, BofA Securities
  • Natalie Artzi, PhD, Assistant Professor of Medicine, HMS 

THE DR. IS IN | Newborn Sequencing and Prevention of Rare Diseases: A New Public Health and Biopharma Challenge

  • Moderator: Jason Gerberry, Managing Director, Global Research, BofA Securities
  • Robert Green, MD, Director, Genomes2People Research Program, BWH; Professor of Medicine, HMS
  • Adam Shaywitz, MD, PhD, CMO, BridgeBio Gene Therapy 

THE DR. IS IN | Leveraging Novel Mechanisms for Accelerated Vaccine and Immunotherapy Development

  • Moderator: Alexandria Hammond, PhD, Associate, Global Research, BofA Securities
  • Mark Poznansky, MD, PhD, Director, Vaccine and Immunotherapy Center, MGH; Professor of Medicine, HMS

Opening Remarks

  • Introducer: Scott Sperling, Co-Chief Executive Officer, Thomas H. Lee Partners; Chairman of the Board of Directors, Mass General Brigham
  • Anne Klibanski, MD, President & CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, HMS
  • Brian Moynihan, Chair & CEO, Bank of America 

Co-Chair Kick Off

  • Moderator: Susan Hockfield, PhD, President Emerita, MIT
  • Miceal Chamberlain, President of Massachusetts, Northeast Region Executive, Bank of America
  • Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS
  • Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham

GCT’s Historic Potential | Priorities and Trade Offs

  • Moderator: Jean-François Formela, MD, Partner, Atlas Venture
  • Pablo Cagnoni, MD, CEO, Rubius Therapeutics
  • Kristen Hege, MD, Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb
  • Andrew Plump, MD, PhD, President, R&D, Takeda
    Catherine Stehman-Breen, MD, CEO, Chroma Medicine 

Manufacturing | Process Control

  • Moderator: John Bishai, PhD, Managing Director, Global Investment Banking, BofA Securities
  • Christopher Murphy, Vice President Viral Vector Services, Thermo Fisher
  • Michael Paglia, COO, ElevateBio BaseCamp, ElevateBio
  • Rahul Singhvi, ScD, CEO, National Resilience, Inc.
  • Ran Zheng, CEO, Landmark Bio

FIRESIDE | Regulatory Perspectives on Gene and Cell Therapy: Past Lessons, Current Challenges, Future Directions

  • Moderator: Luk Vandenberghe, PhD, Grousbeck Associate Professor in Gene Therapy, Mass General Brigham
    Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA

Clinical GCT Trial Design | Regulatory | Strategy, Innovation and Future Direction | Risk vs Hype

  • Moderator: Angela Shen, MD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
  • Laura Aguilar, MD, PhD, Co-Founder, Candel Therapeutics
  • Matthew Frigault, MD, Clinical Director, Cellular Immunotherapy Program, MGH; Assistant Professor of Medicine, HMS
  • Arati Rao, MD, Senior Vice President, Clinical Development, PACT Pharma
  • John Rossi, VP Head of Translational Medicine, Syncopation Life Sciences

FIRESIDE | mRNA Opportunities: Lessons Learned, Priorities, and the Future of GCT

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Albert Bourla, PhD, CEO, Pfizer Inc.

Tuesday, May 3, 2022

FIRESIDE | Robert Califf, MD, Commissioner Food and Drugs, FDA

  • Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
  • Moderator: J. Keith Joung, MD, PhD, Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; Professor of Pathology, HMS
  • Robert Califf, MD, Commissioner of Food and Drugs, US Food and Drug Administration 

Living with COVID | Lessons Learned and Looking Ahead

  • Introducer: Jonathan Kraft, President, The Kraft Group; Chairman of the Board of Trustees, MGH
  • Moderator: David Brown, MD, President, Massachusetts General Hospital; Executive Vice President, Mass General Brigham
  • Paul Biddinger, MD, Chief Preparedness and Continuity Officer, Mass General Brigham; Associate Professor of Emergency Medicine, HMS
  • Helen Branswell, Senior Writer, STAT
  • Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, BWH; Harriet Ryan Albee Professor of Medicine, HMS
  • Erica Shenoy, MD, PhD, Associate Chief, Infection Control Unit, MGH; Associate Professor of Medicine, HMS

The Global Biotech Epicenter | New England Now and in 2030

  • Moderator: Anne Finucane, Chairman of the Board, Bank of America Europe
  • Seth Ettenberg, PhD, President & CEO, BlueRock Therapeutics
  • Joel Marcus, Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.
  • Terry McGuire, Founding Partner, Polaris Partners
  • Vicki Sato, PhD, Chairman of the Board, Vir Biotechnology; Chairman, Denali Therapeutics
  • Phillip Sharp, PhD, Institute Professor and Professor of Biology, Koch Institute for Integrative Cancer Research at MIT; Co-Founder, Alnylam Pharmaceuticals, Inc.

The Patient Experience

  • Moderator: Merit Cudkowicz, MD, Chair, Dept of Neurology, MGH; Julieanne Dorn Professor of Neurology, HMS
  • James Beck, PhD, CSO, Parkinson’s Foundation
  • Monica Coenraads, CEO, Rett Syndrome Research Trust
  • Annie Ganot, VP, Head of Patient Advocacy, Solid Biosciences
  • Staci Kallish, DO, President, Board of Directors, National Tay Sachs and Allied Diseases; Medical Geneticist, Associate Professor of Clinical Medicine, Penn Medicine
  • Rebecca Oberman, PhD, Executive Director, Mucolipidosis Type IV (ML4) Foundation 

FIRESIDE | Meeting the Moment: The Next Wave of Innovation in Cancer and Cardiology

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Robert Bradway, CEO, Amgen 

First Look Award Presentation

  • Presenter: Miceal Chamberlain, President of Massachusetts, Northeast Region Executive, Bank of America
  • Presenter: Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS 

THE DR. IS IN | Personalizing Cancer Care through RNA Therapies

  • Moderator: Jason Gerberry, Managing Director, Global Research, BofA Securities
  • Pierpaolo Peruzzi, MD, PhD, Neurosurgeon and Principal Investigator, BWH; Assistant Professor of Neurosurgery, HMS

THE DR. IS IN | Designing for Success: Clinical Trial Approaches for Rare and Ultra-Rare Diseases

  • Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
  • Demetrios Vavvas, MD, PhD, Associate Director of the Retina Service, Mass Eye and Ear; Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS

THE DR. IS IN | A New Hope: Cell Therapy and Transplantation for Parkinson’s Disease

  • Moderator: Greg Harrison, Vice President, Global Research, BofA Securities
  • Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet Professor of Neurosurgery, HMS
  • Todd Herrington, MD, PhD, Director, Deep Brain Stimulation Program, MGH; Assistant Professor of Neurology, HMS
  • Kwang-Soo Kim, PhD, Director, Molecular Neurobiology Laboratory, McLean; Professor of Neuroscience and Psychiatry, HMS
  • Jeffrey Schweitzer, MD, PhD, Neurosurgeon, MGH; Assistant Professor of Neurosurgery, HMS

THE DR. IS IN | The Inner Workings of Gene Therapy Manufacturing

  • Moderator: Michael Ryskin, Director, Global Research, BofA Securities
  • Sarah Nikiforow, MD, PhD, Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI; Assistant Professor, HMS

THE DR. IS IN | The Road Ahead: Regulatory Challenges for Gene and Cell Therapy

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA

THE DR. IS IN | The Mysterious Dark Genome

  • Moderator: Angela Shen, MD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
  • Moderator: Richard Young, PhD, Professor, Whitehead Institute, MIT
  • Rosana Kapeller, MD, PhD, Co-Founder, President & CEO, ROME Therapeutics
  • Josh Mandel-Brehm, President & CEO, CAMP4 Therapeutics
  • Amir Nashat, PhD, Managing Partner, Polaris Ventures
  • Issi Rozen, Venture Partner, GV

Capital Formation | Shaping Innovation

  • Moderator: Greg Butz, Managing Director, Head of Life Sciences Investment Banking, BofA Securities
  • Moderator: Sumit Mukherjee, Managing Director & Head of Healthcare in Equity Capital Markets, BofA Securities
  • Shelley Chu, MD, PhD, Partner, Lightspeed
  • Stephen Knight, MD, President & Managing Partner, F-Prime Capital
  • Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences
  • Daniel Krizek, Portfolio Manager, Citadel

FIRESIDE | Ending Cancer as We Know It: The Game Changing Potential of GCT

  • Moderator: Erin Harris, Chief Editor, Cell & Gene
  • David Scadden, MD, Director, Center for Regenerative Medicine, MGH; Gerald and Darlene Jordan Professor of Medicine, HMS
  • Norman Sharpless, MD, Former Director, National Cancer Institute 

FIRESIDE | Vision and Execution: Curing Disease with Cell Therapies

  • Moderator: Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH
    Associate Professor, Medicine, HMS
  • Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
  • Carl June, MD, Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine

GCT Development Centers | Academia’s Unique Contribution

  • Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
  • Carl June, MD, Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
  • Maria Millan, MD, President & CEO, California Institute for Regenerative Medicine
  • Richard Mulligan, PhD, Mallinckrodt Professor of Genetics, Emeritus, HMS; Executive Vice Chairman, Sana Biotechnology, Inc
  • Norman Sharpless, MD, Former Director, National Cancer Institute

FIRESIDE | Marc Casper

  • Moderator: Derik de Bruin, PhD, Managing Director, Global Research, BofA Securities
  • Marc Casper, CEO, ThermoFisher

Gene and Cell Therapy | The World Speaks

  • Moderator: Christine Fox, President, Novartis Gene Therapies
  • Christopher Baum, MD, Chairman of the Board of Directors, Berlin Institute of Health at Charité (BIH)
  • Nicholas Galakatos, PhD, Global Head of Life Sciences, Blackstone
  • Luigi Naldini, MD, PhD, Director, San Raffaele Telethon Institute for Gene Therapy
  • Kendra Rose, PhD, VP, Head of New Platforms, Ophthalmology and Hemophilia, Bayer

Control or Mitigation of the Effects of Chronic Neuroinflammation

  • Moderator: Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS
  • Colin Hill, CEO, GNS Healthcare
  • Spyros Papapetropoulos, MD, PhD, CMO, Vigil Neuroscience
  • Richard Ransohoff, MD, CMO, Abata Therapeutics; Venture Partner, Third Rock Ventures
  • Beth Stevens, PhD, HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children’s Hospital; Associate Professor of Neurology, HMS
  • Rudolph Tanzi, PhD, Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS

Wednesday, May 4, 2022

The Cell Therapy Landscape | CAR-T to Stem Cells

  • Moderator: Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS
  • Christina Coughlin, MD, PhD, CEO, CytoImmune
  • Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences
  • Nick Leschly, CEO, 2seventy bio
  • Dhvanit Shah, PhD, President & CEO, Garuda Therapeutics
  • Rusty Williams, MD, PhD, Chairman & CEO, Walking Fish Therapeutics

Disrupting Interventions

  • Introducer: John Fish, Chairman & CEO, Suffolk; Chair, Brigham and Women’s Hospital
  • Moderator: Robert Higgins, MD, President, Brigham and Women’s Hospital; Executive Vice President, Mass General Brigham
  • Irina Antonijevic, MD, PhD, CMO and Head of R&D, Triplet Therapeutics, Inc.
  • Rachel McMinn, PhD, Founder & CEO, Neurogene
  • Harith Rajagopalan, MD, PhD, CEO & Co-Founder, Fractyl Health
  • Bastiano Sanna, PhD, EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals
  • Jeffrey Schweitzer, MD, PhD, Neurosurgeon, MGH; Assistant Professor of Neurosurgery, HMS 

FIRESIDE | Dan Skovronsky

  • Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
  • Daniel Skovronsky, MD, PhD, Senior Vice President, Chief Scientific and Medical Officer, Eli Lilly and Company

FIRESIDE | Reimagining GCT Production

  • Moderator: Derik de Bruin, PhD, Managing Director, Global Research, BofA Securities
  • Jason Kelly, PhD, Co-Founder & CEO, Ginkgo Bioworks

Gene and Cell Therapy Safety | Enduring Framework Required

  • Moderator: Christine Seidman, MD, Director, Cardiovascular Genetics Center, BWH; Smith Professor of Medicine & Genetics, HMS
  • Rick Fair, President & CEO, Bellicum
  • Alexandria Forbes, PhD, President & CEO, MeiraGTx
  • Sekar Kathiresan, MD, CEO, Verve Therapeutics
    Rick Modi, CEO, Affinia Therapeutics

RNA Therapeutics | Lessons Learned

  • Moderator: Janet Wu, Anchor/Reporter, Bloomberg
  • Sarah Boyce, President & CEO, Avidity Biosciences, Inc.
  • Jim Burns, PhD, CEO, Locanabio
  • Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS
  • Laura Sepp-Lorenzino, PhD, Chief Scientific Officer, Executive Vice President, Intellia Therapeutics

Disruptive Dozen: 12 Technologies That Will Reinvent GCT in the Next Five Years

  • Moderator: Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS
  • Moderator: Susan Slaugenhaupt, PhD, Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr. Endowed Chair, Mass General Research Institute; Professor, Neurology, HMS
  • Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
  • Galit Alter, PhD, Principal Investigator, Ragon Institute, MGH; Professor of Medicine, HMS
  • Natalie Artzi, PhD, Assistant Professor of Medicine, HMS
  • Fengfeng Bei, PhD, Principal Investigator, Department of Neurosurgery, BWH; Assistant Professor of Neurosurgery, HMS
  • Zheng-Yi Chen, DPhil, Associate Scientist, Eaton-Peabody Laboratories, Mass Eye and Ear; Associate Professor of Otolaryngology Head and Neck Surgery, HMS
  • Matthew Frigault, MD, Clinical Director, Cellular Immunotherapy Program, MGH; Assistant Professor of Medicine, HMS
  • Michael Gilmore, PhD, Chief Scientific Officer, Mass Eye and Ear; Sir William Osler Professor of Ophthalmology, HMS
  • Allan Goldstein, MD, Chief of Pediatric Surgery, MGH; Surgeon-in-Chief, MassGeneral for Children
  • Anna Krichevsky, PhD, Associate Professor of Neurology, BWH, HMS
  • Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS
  • James Markmann, MD, PhD, Chief, Division of Transplant Surgery, MGH; Claude E. Welch Professor of Surgery, HMS
  • Khalid Shah, PhD, Vice Chairman of Research, Department of Neurosurgery, BWH; Professor, HMS
  • Demetrios Vavvas, MD, PhD, Associate Director of the Retina Service, Mass Eye and Ear; Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS

Sponsors

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA